ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma by Kim, Michael P. et al.
ALDH Activity Selectively Defines an Enhanced Tumor-
Initiating Cell Population Relative to CD133 Expression in
Human Pancreatic Adenocarcinoma
Michael P. Kim
1, Jason B. Fleming
1, Huamin Wang
2, James L. Abbruzzese
3, Woonyoung Choi
4, Scott
Kopetz
3, David J. McConkey
4, Douglas B. Evans
5, Gary E. Gallick
6*
1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 2Department of Pathology, The
University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 3Department of Gastrointestinal Medical Oncology, The University of Texas
MD Anderson Cancer Center, Houston, Texas, United States of America, 4Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas,
United States of America, 5Department of Surgery, The Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America, 6Department of Genitourinary
Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
Abstract
Background: Multiple studies in recent years have identified highly tumorigenic populations of cells that drive tumor
formation. These cancer stem cells (CSCs), or tumor-initiating cells (TICs), exhibit properties of normal stem cells and are
associated with resistance to current therapies. As pancreatic adenocarcinoma is among the most resistant human cancers
to chemo-radiation therapy, we sought to evaluate the presence of cell populations with tumor-initiating capacities in
human pancreatic tumors. Understanding which pancreatic cancer cell populations possess tumor-initiating capabilities is
critical to characterizing and understanding the biology of pancreatic CSCs towards therapeutic ends.
Methodology/Principal Findings: We have isolated populations of cells with high ALDH activity (ALDH
high) and/or CD133
cell surface expression from human xenograft tumors established from multiple patient tumors with pancreatic
adenocarcinoma (direct xenograft tumors) and from the pancreatic cancer cell line L3.6pl. Through fluorescent activated cell
sorting (FACs)-mediated enrichment and depletion of selected pancreatic cancer cell populations, we sought to
discriminate the relative tumorigenicity of cell populations that express the pancreatic CSC markers CD133 and aldehyde
dehydrogenase (ALDH). ALDH
high and ALDH
low cell populations were further examined for co-expression of CD44 and/or
CD24. We demonstrate that unlike cell populations demonstrating low ALDH activity, as few as 100 cells enriched for high
ALDH activity were capable of tumor formation, irrespective of CD133 expression. In direct xenograft tumors, the
proportions of total tumor cells expressing ALDH and/or CD133 in xenograft tumors were unchanged through a minimum
of two passages. We further demonstrate that ALDH expression among patients with pancreatic adenocarcinoma is
heterogeneous, but the expression is constant in serial generations of individual direct xenograft tumors established from
bulk human pancreatic tumors in NOD/SCID mice.
Conclusions/Significance: We conclude that, in contrast to some previous studies, cell populations enriched for high ALDH
activity alone are sufficient for efficient tumor-initiation with enhanced tumorigenic potential relative to CD133
+ and
ALDH
low cell populations in some direct xenograft tumors. Although cell populations enriched for CD133 expression may
alone possess tumorigenic potential, they are significantly less tumorigenic than ALDH
high cell populations. ALDH
high/
CD44
+/CD24
+ or ALDH
low/CD44
+/CD24
+ phenotypes do not appear to significantly contribute to tumor formation at low
numbers of inoculated tumor cells. ALDH expression broadly varies among patients with pancreatic adenocarcinoma and
the apparent expression is recapitulated in serial generations of direct xenograft tumors in NOD/SCID. We have thus
identified a distinct population of TICs that should lead to identification of novel targets for pancreatic cancer therapy.
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Introduction
Pancreatic adenocarcinoma is the fourth leading cause of cancer
mortality in the United States and is characterized by early
metastasis and resistance to conventional therapies [1]. Overall
prognosis for pancreatic cancer patients remains poor due largely
to late diagnosis and our limited understanding of genetic and
epigenetic factors contributing to disease progression and therapy
resistance. In recent years, cancer stem cells (CSCs), also referred
to as tumor-initiating cells (TICs), have been implicated in tumor
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20636formation, progression, and therapy-resistance in multiple solid-
organ cancers, including pancreatic adenocarcinoma [2,3,4,5,6,7,
8,9,10,11,12,13,14,15]. As such, identifying the molecular markers
that best discern pancreatic TIC populations may provide
opportunities to characterize critical molecular pathways involved
in tumorigenesis for targeted therapies [16].
To date, the identification of pancreatic cancer stem cells has
been contingent upon the enrichment of TIC populations through
marker-dependent cell selection. Using this strategy, high activity
of the intracellular enzyme, aldehyde dehydrogenase (ALDH), and
the cell surface markers CD133 and co-expressed CD44/CD24
have been shown individually shown to possess tumor-initiating
properties in different studies [8,13,17]. Thus, whether pancreatic
adenocarcinoma tumors arise from different CSC/progenitor
populations enriched through selection of alternative cell surface/
functional phenotypes (i.e. CD44/CD24, CD133, or ALDH) or
common CSC/progenitor populations exist that expresses shared,
‘‘universal’’ TIC markers remains unclear.
ALDH is an intracellular enzyme involved in retinoic acid
metabolism and its activity has been shown to enrich for normal
and/or malignant stem cell populations in multiple organ systems
including breast, colon, blood, and brain [12,18,19,20].
Many studies of CSCs were initially performed in hematologic
systems[21]. In these systems, further examination of ALDH
high cell
populations for sub-populations also expressing CD133 or CD34
haveidentifiedcommon,primitivemulti-lineageprogenitorandstem
cell populations [22,23]. For example, Hess et al. demonstrated
hematopoietic stem cell populations expressing both ALDH
high and
CD133 possess a 10-fold greater potential for long-term bone
marrow reconstitution relative to cells enriched for CD133
expression alone [22]. In pancreatic cancer, a recent study by
Rasheed et al. demonstrated increased tumorigenic potential of
ALDH
high/CD44
+/CD24
+ and CD44
+/CD24
+ pancreatic cancer
cell populations with ALDH expression correlating with a worse
prognosis in early stage pancreatic cancer patients [17]. These
authors found minimal overlap between ALDH and CD44
+/CD24
+
cell populations (,0.1%), suggesting the existence of at least two
distinct tumor-initiating populations within human pancreatic
tumors [17]. In contrast to the above study, Hermann et al.
identified pancreatic CSCs by the cell surface expression of CD133
and determined that CD133 was expressed in approximately 1–2%
of pancreatic cancer cells[8]. Although ALDH expression was not
examined in this study, co-expression of CD44 and CD24 was
observedin,0.1% of CD133
+CSCs,againsuggestingthepossibility
that multiple, distinct tumor-initiating populations exist in pancreatic
adenocarcinoma. Examination of cell populations common among
both studies, specifically the tumor-initiating capabilities of purified
ALDH, CD133 and ‘‘double positive’’ ALDH
high /CD133
+ cell-
populations, has not been performed previously. Further refinement
of ALDH
high sub-populations based upon cell surface CD133
expression, similar to hematologic systems, may therefore assist in
the identification of more tumorigenic cell populations.
Given the different conclusions reached in separate studies as to
which, if any, single marker enriches for pancreatic TICs, we sought
to determine whether high ALDH activity is a primary determinant
of at least a subset of pancreatic TICs and the sufficiency of
ALDH
high and ALDH
low cell populations for tumor-initiation when
enriched or depleted of cell populations also expressing CD133.
Herein, using a strict, direct xenograft tumor system and limiting
dilutions of sorted human pancreatic cancer cells injected into
NOD/SCID mice, we demonstrate that cell populations enriched
for high ALDH activity alone fulfill the major criteria of a CSC and
efficiently recapitulate the phenotype of the original tumor
independent of CD133 cell surface expression.
Results
Pancreatic cancer cells contain ALDH
high and ALDH
low
cell populations and heterogeneously express ALDH1
We first evaluated ALDH activity and CD133 cell surface
expression ina pancreatic cancer cell line(L3.6pl) previously used to
enrich CSC populations through CD133 cell surface expression[8].
Flow cytometry demonstrated heterogeneous ALDH activity
among L3.6pl cells with an average of 16.2% (median=13.8%)
ALDH
high cells relative to DEAB control samples, whereas CD133
expression was nearly undetectable (0.02%, median=0.17) relative
to isotype controls (Figure 1A, 1B). When plated in ultra-low
attachment plates under conditions favoring the undifferentiated
state, an average of 12 /10,000 L3.6pl cells (median=11.5)
possessed the ability to form spheroid structures and serial sections
of paraffin-embedded spheres demonstrated the infrequent pres-
ence of cells expressing high levels of ALDH1 relative to all other
cells (Figures 1C, 1D). Subcutaneously implanted L3.6pl cells in
nude mice formed tumors with heterogeneous ALDH1 expression.
ALDH1 expressionwasconfined to small clusters of cellsdistributed
throughout the tumors (Figure 1E). CD133 expression was not
detected in indirect xenograft tumors formed from L3.6pl cells (data
not shown).
We next examined ALDH1 expression in primary human
pancreatic adenocarcinoma tumors. To ascertain the intensity
and location of tumor cells expressing ALDH1, we evaluated a
tissue microarray (TMA) comprised of selected regions of
pancreatic adenocarcinoma tumors with matched normal
pancreas controls from 106 untreated patients. Immunohisto-
chemical analysis of the specimens on the TMA demonstrated
heterogeneous ALDH1 expression among patient specimens with
ALDH expression beneath the level of detection in 32/106 (30%)
samples. Low overall ALDH expression (corresponding with an
expression score #2) was recorded in 23/106 (22%) patients
(Figure 2A, see Materials and Methods for determination of
quantitation); moderate overall ALDH expression was observed
in 28/106 (26%) patient samples (Figure 2B, expression score .2
and #4); and high overall ALDH expression was observed in 23/
106 (22%) patient samples (Figure 2C, expression score .4).
These results demonstrate ALDH expression is heterogeneous
among human pancreatic adenocarcinomas. ALDH expression
was observed within luminal tumor cells and was exclusively
confined to the cytoplasm. We next sought to confirm the
presence of ALDH
high and ALDH
low cell populations in freshly
resected pancreatic adenocarcinoma tumors by flow cytometry.
We digested two patient tumors into single cell suspensions and
stained with the AldefluorH reagent, complete with DEAB-
inhibited controls. Each digested patient tumor contained a
single cell population demonstrating intensified ALDH activity
relative to all other human tumor cells when analyzed by flow
cytometry (Figure 2D, 2E). Collectively, these results demonstrate
heterogeneous ALDH activity in individual human pancreatic
tumors with only a minority of cells possessing ALDH
high
activity.
Histologic expression of ALDH1 is conserved in direct
xenograft tumors
To expand tumor specimens available for study, we established a
panel of direct xenograft tumors to provide sufficient specimens for
the study and isolation of pancreatic cancer cell populations. As we
have reported previously, minced patient tumors were heterotop-
ically implanted into NOD/SCID mice [24]. Direct xenograft
tumors were established from surgical specimens resected from 11
different patients with pancreatic adenocarcinoma as confirmed by
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already treated with neoadjuvant therapy (chemotherapy and
radiation) and from patients who had not received any neoadjuvant
therapyasshown inTable 1.Onceengrafted, tumorsweregrownto
a maximum diameter of 1.2 cm and surgically procured for
histologic evaluation and serial implantation into additional
generations of NOD/SCID mice. The overall histologic appear-
ances of direct xenograft tumors (and at least two subsequent
passagesofthesetumors)werenearlyidenticaltotheoriginalpatient
tumors. As shown in the representative H&E image in Figure 3A,
tumor-gland formation and associated peri-tumoral stroma were
evident in all direct xenograft tumors.
We next compared the histologic presence and pattern of
ALDH1-expressing cells in direct xenograft tumors relative to the
parental (patient) tumors from which they were derived. Histologic
evaluation of 12 direct xenografts established from 11 different
patient tumors (one xenograft was derived from a lymph node
metastasis from the same patient in which a xenograft was derived
from a primary tumor) identified a subset cells that strongly
express ALDH1 relative to all other tumor cells in all but one
specimen (four examples are shown in Figure 3B). The patient
specimen, MDA-PATX10, in which ALDH1 was undetectable by
immunohistochemistry also did not express detectable ALDH1 in
derived xenografts (Figure 3B), suggesting that the xeno-trans-
plantation process did not affect ALDH1 expression. Again
consistent with ALDH1 expression in human tumor specimens,
intra-tumoral heterogeneity of ALDH1 expression in direct
xenograft tumors was demonstrated through intense staining for
ALDH1 in only a subset of luminal tumor cells relative to all other
cells within tumor (Figure 3C). All of these characteristics were
maintained in subsequent direct xenograft generations (data not
shown).
Figure 1. ALDH activity and expression in L3.6pl pancreatic cancer cells. (A) Representative example of L3.6pl cells stained with Aldefluor
reagent with and without the DEAB inhibitor as described in Materials and Methods. Analysis by flow cytometry demonstrated high ALDH activity in
approximately 16% of cells. (B) L3.6pl cells stained with directly conjugated CD133 antibodies failed to reveal a significant CD133
+ population relative
to isotype controls. (C) L3.6pl cells form spheres after plating on ultra-low attachment plates (average of 12 spheres/10,000 cells). (D) Cross sections of
spheres were made and stained for ALDH1. A minority of cells contained within spheroids demonstrated strong ALDH1expression. (E) Staining for
ALDH1 in sections of indirect xenograft tumors formed from L3.6pl cells in nude mice. Note small clusters of ALDH positive cells. Scale bar =20 mm
(D), 50 mm (E).
doi:10.1371/journal.pone.0020636.g001
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high and CD133
+ cell populations in
serial generations of NOD/SCID mice bearing
xenografted human tumors
We next sought to identify and quantify overlapping and non-
overlapping cell populations expressing putative pancreatic CSC
markers in direct xenograft tumors by flow cytometry. Pancreatic
tumors of NOD/SCID mice (F2–F4) underwent mechanical and
enzymatic digestion into single cell suspensions and were subse-
quently stained with AldefluorH reagent and directly conjugated
anti-CD133antibodiesasdescribed inMaterialsand Methods.After
exclusionofdebrisandcellsofmouseorigin,viablehumancellswere
analyzed by flow cytometry (see gating strategy, Figure S1).
The results demonstrated ALDH
high and ALDH
low in all
patient-derived xenografts examined, but the proportion of each
varied widely (Figure 4A; Table 1). However, within a given
patient xenograft lineage, the relative percentage of cells with high
ALDH activity remained conserved through at least two passages
in NOD/SCID mice as did the percentage of cell populations with
low ALDH activity.
We next evaluated ALDH
high and ALDH
low cell populations for
expression of CD133 on the cell surface and found the cell subset
ALDH
high /CD133
+ to be the most rarely expressed (range=0.01–
8.2% of all tumor cells) in all direct xenografts (Figure 4A; Table 1).
The percent of ALDH
high /CD133
- tumor cells varied widely
between xenograft tumors derived from different patients, with the
vast majority of cells (60–90%) not expressing ALDH or CD133.
Cell populations enriched for ALDH
high activity are more
tumorigenic than ALDH
low and CD133
+ cell populations
To determine which cell populations possessed the highest
tumor-initiating potential, we injected purified ALDH
high /CD133
+,
ALDH
high /CD133
2,A L D H
low/CD133
+ and ALDH
low/CD133
2
Figure 2. ALDH1 expression and activity in untreated primary pancreatic cancer specimens. Representative images of heterogeneous
ALDH1 expression among patients with pancreatic cancer. Analysis of a TMA comprised of 106 untreated pancreatic tumors demonstrated (A) low
ALDH1 expression in 22% (23/106) of examined patient specimens. (B) Moderate ALDH1 expression was detected in 26% (28/106) of examined
patient specimens. (C) High ALDH1 expression was detected in 22% (23/106) of examined patient specimens. (D) Flow cytometry results of patient
pancreatic adenocarcinoma tumors after digestion into a single cell suspension and stained with Aldefluor reagent, with and without DEAB inhibitor.
Populations of cells with high ALDH activity relative to the overall cell population are easily distinguished. ALDH
high cells=12.7% (Patient 1) and
11.4% (Patient 2) of all viable human cells. Scale bar =250 mm.
doi:10.1371/journal.pone.0020636.g002
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into the subcutaneous flank of NOD/SCID mice in limiting dilutions
(100, 500, and 1000 cells), as described in Materials and Methods. All
mice were monitored for the development of tumors for three months
or sacrificed when tumors exceeded 1.2 cm.
ALDH
high /CD133
2 cells demonstrated the highest incidence of
tumor formation with tumors forming in all immunodeficient mice
implanted with 100 cells (Figure 4B; Table 2). ‘‘Double positive,’’
ALDH
high /CD133
+ cells were not significantly more tumorigenic
than ALDH
high /CD133
2 cells (p=.07). The incidence of tumor
formation was much lower in ALDH
low cells, regardless of CD133
cell surface expression. Implantation of ALDH
low/CD133
2 cells
resulted in a similar incidence of tumor formation relative to
implanted ALDH
low/CD133
+ cell populations in all tested dilutions.
Likewise, the incidence of tumor formation after implantation of
1000 ALDH
low/CD133
+ cells (14.2%) or 1000 ALDH
low/CD133
2
cells (18.2%) was significantly less than ALDH
high /CD133
+ (75%)
and ALDH
high /CD133
2 (100%) cell populations (p=0.04,
p=0.005 and, p=0.007, p=0.0002, respectively). At the lowest
number of injected cells (100 cells), ALDH
high /CD133
2 cell
populations were significantly increased in incidence of tumor
formation (100%) relative to ALDH
low/CD133
+ (0% tumor
incidence) and ALDH
low/CD133
2 (0% tumor incidence) cell
populations. Tumors initiated from ALDH
high populations recapit-
ulatedthehistologicappearanceofparentaltumorcompletewiththe
pattern of ALDH1 expression (Figure 4C). Another large-scale
tumor initiation experiment with identically sorted cell populations
was performed using cells from pooled MDA-PATX1 xenograft
tumors. In contrast to MDA-PATX5 xenograft tumors, MDA-
PATX1 tumors possess low percent CD133
+ cell populations
(,10% tumor cells) and high ALDH
high percent cell populations
(.25%tumorcells).Fromthispopulation,ALDH
high/CD133
2cells
were also able to form tumors with high incidence, although overall
tumor initiation was less in all sorted populations. Collectively, our
findings demonstrate that ALDH
high /CD133
2 pancreatic cancer
cell populations purified from select direct xenograft tumors have
enhanced tumor-initiating potential in NOD-SCID mice relative to
ALDH
low cell populations.
Table 1. Analysis of ALDH activity and/or CD133 cell surface expression in different generations of direct pancreatic cancer
xenograft tumors.
Patient/ treatment status Xenograft generation ALDH
low/CD133
2 ALDH
low/CD133
+ ALDH
high/CD133
2 ALDH
high/CD133
+
MDA-PATX5 F2 68.5 26.1 3.1 0.8
untreated F2 49.32 45.6 2.6 1.32
F3 43.8 46.8 5.4 2.54
F3 41.3 49 6.9 2.7
F3 - - 4.6 -
F3 59.2 37.8 1.8 0.9
F4 - - 4 -
F4 - 15.5 2 -
F4 76.7 21.6 2.1 0.4
F4 86.9 12.6 0.4 0.1
F4 88.4 9.7 1.8 0.1
F4 87.9 8.3 3.6 0.1
F4 69.5 27.8 2 0.7
F4 73.6 23.7 2 0.6
F4 - 6.8 2.3 -
MDA-PATX1 F2 43.1 8.5 42.9 5.5
untreated F2 65.2 4.5 29.1 1.21
F3 71.3 0.9 27.7 0.1
F3 63.5 0.9 35.5 0.1
MDA-PATX13 F1 55.4 16.8 22.3 5.5
treated F1 67.9 17.7 11.3 3.1
F2 50.1 28.7 18.3 2.9
F4 65.5 20.9 12.5 1.1
MDA-PATX2 F2 48.3 31.2 13.2 6.3
untreated F3 37.9 29.2 26.5 6.4
F3 20.8 40.8 26.4 12
MDA-PATX10 F1 97.9 0.1 2 0.01
treated F2 - - 15.2 -
MDA-PATX9 F1 74.6 2.7 22.6 0.1
treated
doi:10.1371/journal.pone.0020636.t001
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high cells produce tumors comprised of
heterogeneous cell populations and recapitulate the
morpho-histology observed in primary and direct
xenograft tumors
We next sought to determine whether tumors formed from
ALDH
high cells resemble the histology of primary tumors and
could generate the different cell populations observed in the
parental direct xenograft tumors. Tumors initiated from 100
ALDH
high/CD133
2 cell populations were digested into single cell
suspensions and subjected to analysis by flow cytometry as
previously described. Tumors formed from ALDH
high/CD133
2
cell populations (derived from MDA-PATX5 direct xenograft
tumors) produced both ALDH
high and ALDH
low cell subpopula-
tions in similar proportions observed in parental tumors
(Figure 5A). Tumors initiated from ALDH
high cells appeared
histologically identical to parental tumors, demonstrating pseudog-
land formation and the same pattern of ALDH expression
(Figure 4C). Taken together, these results demonstrate that tumors
initiated from small numbers of ALDH
high cell populations
recapitulate the histologic appearance of parental tumor and can
reproduce both ALDH
high and ALDH
low cell subpopulations in
tumors.
ALDH
high and ALDH
low cell populations express CD44
and CD24
Previous reports demonstrated the enrichment of CSCs through
the isolation of pancreatic cancer cells co-expressing the cell
surface markers CD44 and CD24[13]. We therefore examined
ALDH
high and ALDH
low cell populations for expression of cell
surface CD44 and CD24 using flow cytometry (Figure 5B).
ALDH
high/CD44
+/CD24
+ cells comprised an average of 0.015%
of all pancreatic cancer cells and ALDH
low/CD44
+/CD24
+ cells
comprised 0.11% of all tumor cells. Among ALDH
high cells,
0.48% (median=0.38) co-expressed CD44 and CD24 and 0.12%
(median=0.14) of all ALDH
low cells were found to express CD44
and CD24 (Figure 5B). Although some increased expression of
CD44 and CD24 was observed in ALDH
high populations relative
to ALDH
low populations, the difference was not significantly
significant (p=0.09).
Expression of ALDH and CD133 in direct xenografts
derived from treated and untreated patient specimens
Multiple studies have shown that CSC populations become
transiently enriched when tumors are subjected to chemotherapy
and radiation [8]. Whether CSC populations are enriched in
Figure 3. Histologic analysis of patient and direct xenograft tumors for expression of ALDH1. (A) Representative image demonstrating
the histologic appearance of direct xenograft tumors established from freshly resected pancreatic tumors. Note tumor-gland formation and
associated peri-tumoral stroma. (B) Comparison of ALDH1 expression in four different direct xenograft tumors to ALDH1 expression in original
(parental) patient tumors. The pattern and location of ALDH1 expression is maintained during the xeno-transplantation process as reflected in
derived xenograft tumors. An example of undetectable ALDH1 expression in both the patient tumor and derived direct xenograft is shown in the
third panel from the top (MDA-PATX10). (C) Intra-tumoral heterogeneity of ALDH1 expression in direct xenograft tumors is readily identified as only a
subset of luminal tumor cells demonstrate intense staining for ALDH1 relative to all other cells within tumor. Scale bar =125 mm (A), 180 mm (B),
125 mm (C).
doi:10.1371/journal.pone.0020636.g003
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with chemotherapy and radiation therapy relative to tumors never
exposed to such therapies remains unknown. We therefore
compared ALDH activity and CD133 expression in xenograft
tumors established from patient tumors treated with chemother-
apy and radiation therapy relative to untreated specimens by flow
cytometry. No general enrichment of either ALDH or CD133
expressing cell populations was observed in tumor specimens
previously exposed to neoadjuvant therapy relative to treatment
naı ¨ve tumor specimens (Table 1). However, because the percent
cell populations of ALDH or CD133 expressing cells remains
unknown in original patient tumors, we are unable to determine
whether such cell populations become enriched or diluted in
formed direct xenograft tumors.
Discussion
We demonstrate that selection for cells with high ALDH activity
from direct pancreatic cancer xenograft tumors enriches for TICs
in the NOD/SCID xeno-transplantation model, with implantation
of only 100 ALDH
high cells resulting in a 100 percent incidence of
Figure 4. Isolation and quantitation of cells expressing high ALDH activity and/or cell surface CD133. (A) Representative images of
digested tumors as analyzed by flow cytometry. After staining digested direct xenograft tumors with directly conjugated CD133 antibodies and the
Aldefluor reagent (BAAA), ALDH
high and CD133
+ cell populations were individually identified by flow cytometry, as described in Materials and
Methods. Cell populations demonstrating high and low ALDH activity and/or CD133 expression were further purified using FACS. (B) Frequency of
tumor formation after xeno-transplantation of cells expressing the specified markers at indicated numbers of inoculated cells. 95% confidence
intervals are shown, *p,0.05. (C) Morpho-histologic appearance by H&E and ALDH expression in tumors initiated by ALDH
high cell populations.
Tumor-gland formation, peri-tumoral stroma, and ALDH1 expression resembles that of parental, xenograft tumor. Scale bar =125 mm (C).
doi:10.1371/journal.pone.0020636.g004
Table 2. Incidence of tumor formation after xeno-
transplantation of purified pancreatic cancer cell populations.
Markers Number of transplanted cells
100 500 1000
ALDH
high/CD133
+ 3/7 2/7 6/8
ALDH
high/CD133
2 6/6 5/8 7/7
ALDH
low/CD133
+ 0/8 2/7 1/7
ALDH
low/CD133
2 0/21 2/19 4/22
*90-day incubation.
doi:10.1371/journal.pone.0020636.t002
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initiation study in this mouse model system examining the tumor-
initiating capacity of pancreatic tumor cell populations based upon
single and shared expression of the CSC markers ALDH and
CD133. The first report of isolation of pancreatic cancer cells with
tumor-initiating properties resulted from selection of cells for
CD44, CD24, and ESA (epithelial-specific antigen) cell surface
expression [13]. In contrast, Hermann et al. identified CD133 as a
marker for tumor initiation in NOD/SCID mice [8]. A recent
study by Rasheed et al. identified ALDH
high cells as possessing
tumor-initiating properties with an incidence of tumor formation
of 20 percent when 50–200 ALDH
high pancreatic tumor cells were
implanted into NOD/SCID mice [17]. In the same study,
ALDH
high/CD44
+/CD24
+ cells initiated tumors in 36 percent
of inoculated mice under identical conditions, but expression of
CD133
+ was not assessed in these cell populations, potentially
important given the relatively low incidence of tumor formation
(20–36 percent) in limiting dilutions of cells enriched for ALDH,
CD44/24, or the combination thereof.
Given the different conclusions reached in separate studies as to
which marker best enriches for pancreatic TICs, we focused on the
relationship of ALDH and CD133 to establish the potential
sufficiency of ALDH
high and/or CD133
+ cell populations to
efficiently initiate tumors. After demonstrating ALDH expression
in a human pancreatic cancer cell line and in primary pancreatic
cancer specimens through histologic analysis and flow cytometry,
we next sought to further distinguish TICs through the purification
of cell sub-populations based upon ALDH activity and/or CD133
cell surface expression from established direct xenograft tumors. In
contrast to hematologic systems, we demonstrate that the ‘‘double
Figure 5. Analysis of direct xenograft tumors by flow cytometry after digestion into single cell suspensions. (A) Tumors initiated from
100 ALDH
high/CD133
2 cells were digested into single cell suspensions and analyzed by flow cytometry following staining with the Aldefluor reagent
and directly conjugated CD133 antibodies. Both ALDH
high and ALDH
low cell populations were present in formed tumors in proportions (% cell
population) similar to parental tumors. (B) Representative image of analysis of ALDH
high and ALDH
low cell populations for co-expression of CD44 and
CD24 by flow cytometry. Small proportions of cells expressing CD44 and CD24 were present in both cell populations. ALDH
high/CD44
+/CD24
+ cell
populations comprised an average of only 0.015% of all viable, human pancreatic cancer cells and an average of 0.48% of all ALDH
high cells.
doi:10.1371/journal.pone.0020636.g005
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high /CD133
+ phenotype is not significantly more
tumorigenic than the ALDH
high /CD133
2 phenotype in examined
directxenograft tumorswith both cell phenotypes significantly more
tumorigenic than ALDH
low cell populations. Tumors formed with
100 percent incidence from as few as 100 ALDH
high /CD133
2 cells
after xeno-transplantation in NOD/SCID mice, maintained the
histologic appearance of the original tumor, and produced both
ALDH
low and ALDH
high cell populations while re-establishing their
relative prevalence (percent of all tumor cells) observed in parental
tumors. A significantly reduced incidence of tumor formation was
observed in cell populations enriched for CD133 alone relative to
ALDH
high cell populations with minimal tumor formation observed
in cell populations depleted of ALDH
high cells. Our results therefore
implicate high ALDH activity as a more efficient and robust marker
of pancreatic TIC populations than CD133 in the NOD/SCID
mouse model system from the direct xenograft tumors we
examined.
It should also be emphasized that we observed tumor formation
from as few as 500 cells enriched for CD133 cell surface
expression. Although not statistically different than CD133
2 cell
populations (p=0.29), the tumor-initiating potential of cells
enriched for CD133 is well documented in multiple studies from
malignancies from various organ systems, including pancreatic
cancer. A possible explanation for observed tumor formation from
xeno-transplanted CD133
2 and ALDH
low cell populations,
particularly when more cells are inoculated, is contamination
with more tumorigenic cells during high-volume cell sorting.
Despite strict gating strategies under ‘‘gentle FACs’’ conditions,
evaluation of sorted cell populations demonstrated .90% purity,
reflecting inherent limitations in the fidelity of current cell sorting
technologies. Our findings therefore do not strictly refute CD133
as a CSC marker, but merely identify a more tumorigenic cell
population within the same tumors we analyzed, i.e. ALDH
high
cell populations. These findings are in line with other studies that
have observed tumor formation in limiting dilutions from cell
phenotypes with less robust tumor-initiation capacity [10,13].
As we have clarified the tumorigenic potential of distinct and
overlapping populations of cells expressing ALDH and CD133, we
also examined ALDH
high and ALDH
low cell populations for the
co-expression of the cell surface markers CD44 and CD24. As
discussed above, CD44 and CD24 have previously been identified
as pancreatic CSC markers and represent a very small percent of
the population of all tumor cells (0.1%) [13]. All examined
xenograft tumors revealed very small overlap between CD44
+/
CD24
+ and ALDH
high or ALDH
low cell populations, representing
0.015% and 0.11% respectively, of all viable, human tumor cells.
We observed an approximate 4-fold enrichment of CD44
+/
CD24
+ cells in purified ALDH
high cell populations relative to
ALDH
low cell populations, a difference that was not statistically
different due, in part, to limited sample size. Given the extreme
rarity of ALDH
high/CD44
+/CD24
+ cells in direct xenograft
tumors (0.015% of all tumor cells), purification of ALDH
high/
CD44
+/CD24
+ cells was not technically feasible due to extended
cell-sorting times and the mass quantity of tumor required to
obtain even a small number of such cells. Moreover, given the low
incidence of CD44
+/CD24
+ expression within ALDH
high cell
populations (0.48% of ALDH
high cells), the presence of even one
ALDH
high/CD44
+/CD24
+ cell among 100 implanted ALDH
high
cells is quite unlikely and, further still, would not likely account for
the 100% incidence of tumor formation we observed within this
purified cell sub-population. Taken together, these results provide
further evidence that sorting for the ALDH
high cell population
alone is sufficient to enrich for highly tumorigenic cell populations
and that the low incidence of ALDH
high/CD44
+/CD24
+ cells
within purified ALDH
high cell populations implies that this cellular
phenotype it is not a major contributor to tumor initiation. Our
findings therefore suggest that high ALDH expression alone
efficiently defines pancreatic TIC populations, a result consistent
with other studies involving breast, ovarian, colon, and brain
malignancies [2,3,4,5,12,20].
A recently described complication in assessing the potential for
tumor-initiation from sorted cells has been the strain of immune-
deficient mouse used to study. For example, in melanoma, the
incidence of tumor formation is very different in interleukin-2
receptor gamma chain (NSG) mice than in NOD-SCID mice
[25]. However, Ishizawa et al. demonstrated recently that the
frequency of tumor-initiating cells was higher in NSG than in
NOD/SCID mice in only some tumors, but remained relatively
similar in pancreatic and several other solid tumors where
ALDH
high cells were examined for tumor initiation capacity [26].
Thus, in pancreatic cancer, the mouse strains used to date do not
appear to affect the frequency of tumor initiation, further
supporting the idea that CD24/CD44 cells in ALDH
high and
ALDH
low populations are unlikely to contribute to tumor
initiation in our studies.
Another important observation from our study is the inter-
tumoral heterogeneity observed in regard to ALDH expression
among patient and patient-derived xenografts. The relative
percentage of ALDH
high cells was generally maintained in several
generations of direct xenograft models despite some fluctuations
within same-generation xenografts derived from common patient
specimens. Such fluctuations may be technical in nature and due to
varying degrees of xenograft tumor digestion, despite strict
adherence to a functional protocol for the digestion of bulk tumor
specimen. Analysis of direct xenograft tumors using flow cytometry
yielded ALDH
high cell populations constituting 1–37% of all human
tumor cells. The overall percent cell population of ALDH
high cells
was furthermore re-established in tumors formed from as few as 100
ALDH
high cells, implying the presence of a persistent, fixed sub-
populationof TICs. Interestingly,tumorsderived from patients who
underwent neoadjuvant therapy were not enriched in either
ALDH
high or CD133
+ cells following xeno-transplantation. These
findings are consistent with CSC theory which posits that small
populations of CSCs may survive treatment and become transiently
enriched, restoring tumor cell heterogeneity when more differen-
tiated progeny are ultimately produced. It is therefore not surprising
that once re-established in NOD/SCID mice, tumors derived from
treated patients did not demonstrate any sustained enrichment in
ALDH
high or CD133
+ cell populations compared to tumors derived
from untreated patient tumor specimens. Further investigations are
required to determine whether putative CSC populations are
enriched during chemo-radiation therapy in human pancreatic
cancer patients and to isolate such populations for intense study
towards therapeutic ends.
Methods
Ethics Statement
All surgically resected pancreatic tumors were collected after
written patient consent and in accordance with the institutional
review board-approved protocols of the University of Texas M.D.
Anderson Cancer Center (protocol LAB07-0854). All animals are
housed and maintained under guidelines established by the
American Association of Laboratory and Animal Care and animal
experiments are performed in accordance with NIH-Animal Care
and Use Committee (ACUC) guidelines (protocols 09-07-10131
and 03-10-01431) after the University of Texas M.D. Anderson
Cancer Center IRB approval.
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The L3.6pl cell line was a gift from the laboratory of Dr. I.J.
Fidler (The University of Texas M.D. Anderson Cancer Center)
and was isolated from liver metastases after serial orthotopic
implantation of the human pancreatic cancer cell line COLO357
in nude mice [27]. L3.6pl cells were maintained as a sub-confluent
monolayer in MEM supplemented with 10% fetal bovine serum
(Hyclone Laboratories, Waltham, MA), 2 mmol/L glutamine, and
a penicillin-streptomycin mixture. All cells were incubated in 5%
CO2 at 37uC. Cells were routinely screened for Mycoplasma and
found to be Mycoplasma-free. For sphere formation assays, L3.6pl
cells were counted with a haemocytometer and diluted to
10,000 cells/mL in stem cell media. Stem cell media was freshly
made in DMEM/F12 (Hyclone Laboratories) supplemented with
1X B-27 supplement (Gibco, Carlsbad, CA), epidermal growth
factor (EGF) (Invitrogen, Carlsbad, CA), and basic fibroblast
growth factor (Invitrogen). One milliliter of cell suspension
(10,000 cells/mL) was then plated into each well of 6-well ultra
low-attachment plates (Corning, Lowell, MA) with an additional
0.5 ml of stem cell media added to each well every 2 days. After
seven days, spheres were visualized and counted using light
microscopy.
Establishment of human pancreatic cancer xenografts
The establishment of direct heterotopic xenograft tumors in
NOD/SCID mice has been described previously [24]. All NOD/
SCID were purchased from the National Cancer Institute
(Bethesda, Maryland). 4–6 week-old NOD/SCID mice were
anesthetized with intra-peritoneal injections of a ketamine/
xylazine cocktail and minced tumor fragments were implanted
in subcutaneous flanks. Once grown to 1.2 cm in largest
dimension, mice were sacrificed and tumor passaged into the
subcutaneous flank of additional NOD/SCID mice.
Immunohistochemistry
Paraffin-embedded human tumor samples, xenograft tumors,
and cultured spheres were serially sectioned and deparaffinized in
xylene and rehydrated in alcohol. Antigen retrieval was accom-
plished using citrate buffer pH6.0 and a conventional steamer
followed by blocking in serum solution [28]. ALDH1 anti-human
antibody (BD Biosciences, Franklin Lakes, NJ) was diluted 1:100
and incubated with tissue sections overnight at 4uC. Pure CD133
anti-human antibody (Miltenyi Biotec, Germany) was diluted
1:500 and incubated with tissue sections overnight at 4uC.
Secondary antibodies used for immunohistochemistry were
biotinylated goat anti-rabbit (Biocare Medical, Concord) diluted
1:500 and developed using 3 39 diaminobenzidine tetrahy-
drochloride (DAB). Slides were counterstained with hematoxylin
and coverslipped with permount. Tissue samples were incubated
with mouse IgG1 isotype controls (BD Biosciences, Franklin Lakes,
NJ) and did not demonstrate any specific staining (Figure S2).
Tissue microarray (TMA) evaluation of ALDH1 expression
in human pancreatic ductal adenocarcinoma samples
A TMA composed of 106 human pancreatic ductal adenocar-
cinoma samples was prepared in the Department of Pathology at
the University of Texas M.D. Anderson Cancer Center. For each
tumor, two cores from representative areas of the tumor and one
core from paired benign pancreatic tissue from the same patient
were included. Both the intensity of antibody staining for ALDH1
and the gross percentage of ductal carcinoma cells demonstrating
ALDH1 expression were assessed visually and graded. The
intensity of ALDH1 staining was graded on a scale 0–3:0= no
staining; 1= weak staining; 2= moderate staining; 3= strong
staining. Likewise, the percentage of tumor cells positive for
ALDH1 expression was graded on a scale from 0–3:0= no cells
positive; 1= ,10% positive cells; 2=10–25% positive cells; 3=
.25% positive cells. Only ductal carcinoma cells were assessed
and included in our analysis of pancreatic cancer specimens and
matched controls (normal pancreas).
Digestion of pancreatic tumors and flow cytometry
Xenograft tumors were dissected from host mice and minced
with sterile scalpels in serum-free RPMI (Hyclone Labora-
tories) supplemented with type IV collagenase (200 units/mL,
Worthington Biochemical, Lakewood, NJ) [24]. The cell solution
was then sequentially passed through 70 mM and 40 mMn y l o n
filters and incubated with RBC lysis buffer (eBioscience, San
Diego, CA) for 10 minutes. The resulting single cells were then
centrifuged and re-suspended in Aldefluor assay buffer (Stemcell
Technologies, Vancouver, Canada) and counted with the aid of a
haemocytometer. Cells were stained with the following directly
conjugated monoclonal antibodies in the presence of FcR
blocking reagent (Miltenyi Biotec): anti-mouse CD31-PE (phy-
coerythrin, Miltenyi Biotec), anti-mouse CD45-PE (BD Biosci-
ences), anti-human CD133-APC (allophycocyanin, Miltenyi
Biotec), anti-mouse H-2K
d-PE (BD Biosciences), anti-human
CD44-APC (BD Biosciences), and CD24-PE (BD Biosciences).
The Aldefluor assay was performed per manufacturer’s instruc-
tions (Stemcell Technologies) complete with DEAB controls. IgG
isotype controls corresponding to each directly conjugated
fluorophore were utilized to identify, quantify, and positively
select desired cell populations. All analyses and cell sorting were
performed on a BD FACSAria II (BD Biosciences) using
FACSDiva (BD Biosciences) and FlowJo (Tree Star, Ashland,
Oregon) software. Debris and cell clusters were excluded during
side-scatter and forward-scatter analyses and cell viability
determined using propidium iodide dye exclusion. Cells of
mouse origin, including hematopoietic and endothelial progen-
itor cells, were removed through PE (phycoerythrin) exclusion. A
100-mm ceramic nozzle (BD Biosciences), sheath pressure of 25
pounds per square inch (PSI), and an acquisition rate of 1,000–
5,000 events per second were used as conditions for cell sorting.
Purity of sorted cell populations was routinely confirmed (.90%)
through immediate flow cytometric analysis of pre-sorted cell
populations.
Xeno-transplantation of sorted human pancreatic cancer
cells
Sorted cells were collected in sterile RPMI (Hyclone Labora-
tories) supplemented with 20% FBS chilled to 4uC. Sorted cells
were then counted with a haemocytometer and serially diluted to
desired concentrations in HBSS (BD Biosciences) containing 10%
Matrigel (BD Biosciences) and kept on ice. NOD/SCID mice were
anesthetized with a ketamine/xylazine cocktail and sorted cells
were vortexed and immediately injected into the subcutaneous
flanks with a 25G needle after the region was sterilized with a 70%
ethanol solution. Mice were monitored until fully recovered from
the effects of anesthesia and examined bi-weekly for tumor
formation.
Statistics
Differences in incidence of tumor formation among sorted cell
populations were examined using the Fisher exact test. Differences
in percent cell populations expressing CD44 and CD24 were
evaluated using the Student’s t-test.
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Figure S1 Strategy for analysis and isolation of viable,
human pancreatic cancer cells from direct pancreatic
cancer xenograft tumors.
(JPG)
Figure S2 Representative images of direct xenograft
tumor sections stained with ALDH1A1 antibodies in
parallel with appropriate IgG isotype controls. Cytoplas-
mic staining was clearly visualized in tissue sections incubated with
the ALDH1A1 antibody but not in tissue sections incubated with
IgG controls.
(JPG)
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